Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017.

Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365-7

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Breast Cancer Research and Treatment
TMK
2017
The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Goebell, P.J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Welslau, M., 2017.

Future Oncol 0(0). doi:10.2217/fon-2017-0083 (epup ahead of print)

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Future Oncology
PAZOREAL
2017
Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study.

Schröder, J., Fietz, T., Köhler, A., Petersen, V., Tesch, H., Spring, L., Fleitz, A., Jänicke, M., Marschner, N., 2017.

Eur J Cancer 79, 139–148. doi:10.1016/j.ejca.2017.03.031

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: European Journal of Cancer
TMK
2017
Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W., Marschner, N., Jänicke, M., Hipper, A., Karatas, A., Sebastian, M., Thomas, M., Schirmacher, P., 2017.

J Thorac Oncol 12(1)(MA08.02), S385. doi:10.1016/j.jtho.2016.11.435

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ELCC (IASLC) / Journal: Journal of Thoracic Oncology
CRISP
2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski, C.C., Staib, F., Göhler, T., Hebart, H., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A., Wierecky, J., Boller, E., Indorf, M., Wörns, M.-A., Galle, P.R., Moehler, M., 2017.

J. Cancer Res. Clin. Oncol. 143(6), 1023–1034. doi:10.1007/s00432-017-2344-3

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: - / Journal: Journal of Cancer Research and Clinical Oncology
DERMATUX
2017
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.

Marschner, N., Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuter, U., Busies, S., 2017.

J Oncol Pharm Pract 23(4), 288–295. doi:10.1177/1078155216632379

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Journal Oncology Pharmacy Practice
TNK
2017
Prognosefaktoren für das Überleben von Patienten mit fortgeschrittenem Nierenzellkarzinom – Daten aus dem deutschen prospektiven RCC-Register.

Goebell P.J., Müller L., Staehler M., Müller M., Frank M., Kruggel L.,
Jänicke M., Marschner N., RCC Registry Group, 2017.

Oncol Res Treat 2017;40(suppl 3):1–134

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TNK
2017
Molekulare Testung, molekulare Veränderungen und Erstlinienbehandlung von Patienten mit Nicht-Kleinzelligem Lungenkrebs (NSCLC) in Deutschland. Erste Ergebnisse der Klinischen Register Plattform CRISP (AIO-TRK-0315).

Griesinger F., Eberhardt W.E., Nusch A., Reiser M., Losem C., Ketzler-Henkel S., Zahn M.-O., Marschner N., Jänicke M., Fleitz A., Spring L.,Sahlmann J., Hipper A., Karatas A., de Wit M., Metzenmacher M., Waller C.F., Kern J., Weichert W., Sebastian M., Thomas M., 2017.

Oncol Res Treat 2017;40(suppl 3):1–168

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2017
Patient advocacy session: Registries, databases and statistical modelling. Making MBC count : The new German Cancer Registry.

Marschner, N. 2017

The Breast, Volume 36, Supplement 1, 2017, Page S8.
https://doi.org/10.1016/S0960-9776(17)30617-3

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: The Breast
Registerübergreifend
2017
MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Schmid, P., Ferreira, M., Dubey, S., Zaiss, M., Harper-Wynne, C., Makris, A., Brown, V., Kristeleit, H., Patel, G., Perelló, A., Jones, A., Mithal, N., Ruiz, I., Kümmel, S., Brunt, A.M., Guerra, J.A., Cao, M.G., Saura, C., Mousa, K., Sarker, S.-J., Coetzee, C., Swann, R., Cortes, J., 2016.

Cancer Res 76(4 Supplement), OT1-03-12-OT1-03-12. doi:10.1158/1538-7445.SABCS15-OT1-03-12

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: SABCS / Journal: Cancer Research
MANTA
2016